Development of new preservation solution to maintain vascular endothelial Integlity.

A.探讨血管反应性物质对器官保存的影响。血管活性物质可减少中性粒细胞对再灌注肝组织的浸润。在肝全血管闭塞模型中，即使在2小时完全肝热缺血后，它们也能促进肝组织血流量的维持。此外，他们试图显著恢复肝脏能量代谢。例如，我们尝试了一种全新的rho相关蛋白激酶y27632，以证明rho激酶即使在肝脏缺血再灌注损伤中也能发挥关键作用。雄性SD大鼠建立70%部分肝缺血模型。将动物分为两组，未给药组和在热缺血90 min前给药10mg/kg Y-27632 p.o组，观察动物存活率、动脉压、心率、肝组织血流量、ALT、ET-1、Hyauronic acid、MPO活性、Mac-1染色及病理史。治疗显著改善了存活、肝组织血流量、ALT、ET-1、HA和MPO，并减少了Mac-1阳性中性粒细胞浸润到肝组织的数量。采用HTK溶液冷保存72小时的犬肾自体移植模型，对新物质依达拉奉的自由基清除能力进行了检测。动物随机分为两组，治疗组和对照组。移植前系统输注依达拉奉，移植后系统给药。治疗未证实尿量，NAG/Cr, fea，降低Cr水平，急性肾小管坏死，肾草案丙二醛水平。

A. The effect of vaso-reactive substances on the organ preservation were investigated. Vaso-active substances could reduce neutrophil infiltration into reperfused liver tissue. They also promoted the maintenance of hepatic tissue blood flow even after 2hr complete hepatic warm ischemia using total hepatic vascular occlusion model. Moreover, they attempted remarkable recovery of hepatic energy metabolism.B. For example, we tried a brand new Rho-associated protein kinase, Y 27632 to prove that Rho-kinase can play a key role even in the hepatic ischemia reperfusion injury. Male SD rats were engaged in a 70% partial hepatic ischemia model. Animals were divided into two groups, a no-treated group, a group treated with 10mg/kg Y-27632 p.o before 90 min warm ischemia, Survival, arterial pressure, hart rate, hepatic tissue blood flow, ALT, ET-1, Hyauronic acid, MPO activity, Mac-1 stain, and pathological history were investigated. The treatment ameliorated survival, hepatic tissue blood flow, ALT, ET-1, HA, and MPO, significantly, and also reduced the number of Mac-1 positive neutrophil infiltration into liver tissue.C. A brand new substance, edaravone, was tested for its ability as a radical scavenger using canine kidney auto transplantation model after 72hr cold preservation in HTK solution. Animal were randomly divided into two groups, treated one and untreated control. Edaravone was infused systematically before graft procurment, given into preservation solution, and administered systematically after grafting. The treatment unproved urine volume, NAG/Cr, FENa, and lessened Cr level, acute tubular necrosis, and MDA level in kidney draft.